SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices surge to new highs, driven by a weakening dollar and global economic uncertainty. Community discussions revolve around whether this rally is sustainable or indicative of a larger market bubble, with some anticipating a significant correction while others remain bullish due to geopolitical tensions and potential Federal Reserve actions.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions around potential HR downsizing and restructuring efforts, possibly linked to increased AI spending. The community is analyzing technical indicators for potential trading strategies, while also debating the company's valuation and future growth prospects in a competitive tech landscape. Some traders are expressing frustration with the stock's recent performance.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders debate its correlation to Bitcoin's price movements and potential S&P 500 inclusion, with some expressing frustration over its recent performance. Community members are actively discussing dip-buying opportunities and potential catalysts, including speculation around a Joe Rogan podcast appearance by Michael Saylor. Concerns linger about dilution and the stock's ability to capture Bitcoin's upside, while others remain bullish, citing long-term potential and accumulation phases.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss its potential transition into an AI infrastructure play, fueled by the launch of Black Pearl Phase 1 and rumors of a hyperscaler deal. Community members are weighing the risks and opportunities, with some suggesting profit-taking while others advocate holding for long-term gains in the data center sector. The stock's volatility and sensitivity to broader market trends are also key talking points.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending amid volatility and a significant price correction after a substantial run-up, with community discussions focused on whether this marks the end of the quantum computing hype cycle or a buying opportunity. Concerns about high valuations, potential stock dilution, and insiders selling shares are being weighed against the long-term potential of quantum computing and recent endorsements from major financial institutions. Some traders are betting against the stock, while others remain bullish, anticipating a rebound.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as the community debates its valuation and recent partnerships, including a deal with Swiss Quantum Technology SA. While some express concerns about insider selling and question the company's revenue, others highlight its technology advancements and potential for future growth in the quantum computing sector. The stock's high volatility and the broader discussion around quantum computing's commercial viability are also fueling the conversation.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders react to market volatility and potential trade tensions, with community members actively discussing hedging strategies and positioning for potential market downturns. The ETF's price action and its relationship to broader market indices like the SPY are also being closely monitored. Some traders express concerns about the ETF's management and performance relative to the VIX.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending due to volatility following a recent equity offering, sparking debate among traders about whether it represents smart growth funding or potential shareholder dilution. Community members are actively discussing the company's drone and AI technology, its potential impact on the defense sector, and the possibility of a significant rebound or further downside.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc (QUBT) is trending amid ongoing debates about the viability and valuation of quantum computing stocks, with discussions focusing on the company's financial health after a recent capital raise. Some community members are questioning the necessity of raising so much capital and highlighting potential dilution risks, while others express optimism about QUBT's technology and future prospects in the sector. Comparisons with sector peers like IONQ and RGTI are common, with some arguing QUBT has more room to run.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending due to positive Phase 3 trial results for its essential tremor treatment, sparking significant community discussion about its potential and future prospects. While some traders are optimistic about the stock's potential for further gains, others are wary of a potential offering and are considering short positions, contributing to the volatility and heightened interest in the stock. Analyst upgrades and potential peak sales are being heavily discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

RBC Capital, Jefferies, and TD Cowen raised their price targets on BioCryst after the company announced plans to acquire Astria Therapeutics in a $700 million deal, with analysts calling the sell-off overdone and the combination strategically sound.<a href="https://stocktwits.com/symbol/BCRX">BioCryst shares</a> fell 8.8% to $6.42 on Tuesday, marking their fourth straight session of losses and the biggest single-day drop in nearly eight months, before edging up 1% in after-hours trading.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/ATXS">Astria Therapeutics’ stock</a> jumped 37.1% to $11.61 on Tuesday, its best day in nearly five years and highest level in almost a year, extending gains for a second straight session.RBC Capital raised its price target on BioCryst Pharmaceuticals to $15 from $14 and kept an 'Outperform' rating, saying Tuesday’s weakness in the stock presents a “compelling buying opportunity.” The firm said its confidence increased following BioCryst’s acquisition of Astria Therapeutics and discussions with management, adding that the deal sets up their franchise even better.Jefferies also raised its target on BioCryst to $15 from $14 while maintaining a 'Buy' rating. Analyst Maury Raycroft said the valuation reflects a discount due to a crowded hereditary angioedema (HAE) landscape, potential clinical and regulatory risks, and the need for FTC clearance, but added that the acquisition structure, under which Astria shareholders will own about 15% of the combined company, makes competing bids less likely.Meanwhile, TD Cowen reinstated coverage of BioCryst with a 'Buy' rating and a $30 price target, citing the company’s plan to acquire Astria’s Phase 3 injectable HAE prophylaxis candidate navenibart. The firm said navenibart, a plasma kallikrein inhibitor with strong proof of concept and high key opinion leader interest, is “de-risked.”&nbsp;BioCryst said on Tuesday that it will acquire Astria for $13 per share, valuing the company at about $700 million in enterprise value. The transaction, approved by both boards, is expected to close in the first quarter of 2026. BioCryst will finance the $8.55-per-share cash portion through a mix of existing cash and a new $550 million facility from Blackstone, with the rest paid in BioCryst stock.Astria’s navenibart, designed for quarterly or semi-annual injections, could expand BioCryst’s reach in the HAE market by complementing its existing oral therapy. BioCryst CEO Jon Stonehouse said the deal enables the company to “build out a comprehensive portfolio” that meets patient needs regardless of treatment preference.On Stocktwits, retail sentiment for both BioCryst and Astria was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said they had grown more positive on the Astria deal, noting that if the acquired asset is approved, it could make BioCryst’s revenue growth sustainable for years, which would help the company’s valuation even if some concerns remain.<stembedurl>https://stocktwits.com/luvpizza2/message/632344600</stembedurl>Another bullish user said the stock’s performance looked solid despite dilution, arguing that using undervalued shares to acquire a high-potential growth asset like Astria was a smart strategic move and could significantly boost BioCryst’s long-term worth.<stembedurl>https://stocktwits.com/Uptrending21/message/632308543</stembedurl>While BioCryst’s stock has declined 15% so far in 2025, Astria’s stock has risen 30% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

While BioCryst’s stock (BCRX) has declined 15% so far in 2025, Astria’s stock (ATXS) has risen 30% over the same period. (Photo credit: Getty Images)

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play

The deal, valued at $700 million and backed by new Blackstone financing, is expected to close in early 2026.

Equity

Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst Pharmaceuticals Inc. (BCRX) announced on Tuesday that it has struck a definitive deal to acquire Astria Therapeutics Inc.(ATXS), a clinical-stage biotech firm developing treatments for rare allergic and immunologic conditions.&nbsp;The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value. The acquisition, approved unanimously by both companies’ boards, is expected to close in the first quarter of 2026.To support the acquisition, BioCryst will fund the $8.55-per-share cash portion through a mix of cash on hand and a new financing facility from Blackstone, which offers up to $550 million in capital. The remainder of the consideration will be paid in BioCryst stock. Astria shareholders will own about 15% of the combined entity upon close.<a href="https://stocktwits.com/symbol/BCRX">BioCryst Pharmaceuticals’ stock</a> traded over 8% lower in Tuesday’s premarket.&nbsp;Astria’s flagship asset, navenibart, is a long-acting monoclonal antibody designed to prevent hereditary angioedema (HAE) attacks. Currently in Phase 3 trials, it offers a potential shift in care with its quarterly or semi-annual injection schedule. BioCryst aims to integrate navenibart alongside its existing oral therapy for HAE, creating a complementary treatment offering.“We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference,” said CEO&nbsp; of BioCryst, Jon Stonehouse. “Navenibart can emerge as the injectable of choice for patients seeking infrequent, pain-free dosing, strong attack control, and a mechanism of action they know and understand.”The deal gives BioCryst access to a market of roughly 5,000 patients in the U.S. who currently rely on injectable prophylaxis.&nbsp;BioCryst Pharmaceuticals’ stock has lost over 5% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uuuu-stock-on-track-to-hit-14-year-highs-as-critical-minerals-sector-continues-to-see-strong-investor-interest/ch6mn1qR3mJ">UUUU Stock On Track To Hit 14-Year Highs As Critical Minerals Sector Continues To See Strong Investor Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of the biopharmaceutical company Curevac.

BioCryst To Acquire Astria Therapeutics In $700M Deal

The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value.

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed...

Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround 

BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. (BCRX) is now looking forward to data on its Netherton Syndrome and DME pipeline programs after its second-quarter earnings beat Wall Street expectations on the strong performance of its Orladeyo drug.“Our Netherton Syndrome and DME (diabetic macular edema) pipeline programs remain on track to have some data by the end of the year,” said CEO Jon Stonehouse on the company’s earnings call on Monday. The company is enrolling patients for an early-stage trial of both investigational drugs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_11_07_20_AM_png_98d2936188.webp" alt="BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock’s fair valuation is double its current level.<stembedurl>https://stocktwits.com/doublebtx/message/623619202</stembedurl>Another expressed disappointment at the stock’s slow rally.<stembedurl>https://stocktwits.com/coleslaugh/message/623622668</stembedurl>Netherton syndrome is a rare genetic disorder primarily affecting the skin, hair, and immune system, in which patients experience severe skin problems, including redness, scaling, and blistering, as well as hair abnormalities like bamboo hair.DME, meanwhile, is a leading cause of vision loss in people with diabetes. Fluid accumulates in the central part of the eye’s retina, causing swelling and blurry or distorted vision.A company spokesperson said on the call that the firm is looking at data on several endpoints, including the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin with its investigational drug for Netherton syndrome. For the company’s investigational drug for DME, the company is looking at the effect of the drug on the retina and the potential for reducing the swelling in the retina after a dose of the drug.For the second quarter, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-second-quarter-2025-financial-results-and">reported</a> total revenue of $163.35 million, compared to $109.33 million in the corresponding quarter of 2024, and above an analyst estimate of $149.22&nbsp;&nbsp;&nbsp;&nbsp;million, as per data from Fiscal AI.Orladeyo, the company’s medicine used to prevent attacks of hereditary angioedema (HAE), accounted for a whopping 96% of the company’s total revenue in the quarter. Orladeyo's net revenue in the quarter jumped 45% to $156.8 million.For the full year, the company now expects global net Orladeyo revenue to be between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business. Biocryst in June said that it has entered into a definitive agreement to sell its European Orladeyo business to Neopharmed Gentili for up to $264 million. Closing of the transaction is expected by early October.The company said that it also remains on track to deliver net income and positive cash flows for the full year 2025.BCRX stock is up by about 12% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-announces-purchase-of-blade-urban-air-mobility-business/chrXN6wRdTY">Joby Aviation Stock Flies 15% After Company Announces Purchase Of Blade’s Urban Air Mobility Business: Retail’s Not Entirely Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.